Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-0.43 |
-0.39 |
0.04 |
9.30% |
2024-02-27 |
2023-12 |
-0.46 |
N/A |
N/A |
N/A |
2024-02-27 |
2023-12 |
-0.46 |
-0.4 |
0.06 |
13.04% |
2023-11-09 |
2023-09 |
-0.38 |
N/A |
N/A |
N/A |
2023-11-09 |
2023-09 |
-0.38 |
-0.43 |
-0.05 |
-13.16% |
2023-08-08 |
2023-06 |
-0.38 |
-0.38 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-04 |
Needham |
Upgrade |
Buy |
Buy |
2023-08-08 |
Needham |
Upgrade |
Buy |
Buy |
2023-07-20 |
Needham |
Upgrade |
Buy |
Buy |
2023-07-17 |
Needham |
Upgrade |
Buy |
Buy |
2023-07-12 |
Morgan Stanley |
Upgrade |
Equal-Weight |
Equal-Weight |
2023-07-12 |
Keybanc |
Upgrade |
Overweight |
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2024-05-27 |
BORGESON BLAKE CHARLES |
Director |
7.19M |
Sale |
2024-03-31 |
BURRELL TERRY-ANN |
Director |
56.31K |
Stock Award(Grant) |
2024-03-31 |
CHAVEZ R MARTIN |
Director |
60.08K |
Stock Award(Grant) |
2024-03-31 |
DAR ZAVAIN |
Director |
89.06K |
Stock Award(Grant) |
2024-05-01 |
GIBSON CHRISTOPHER C |
Chief Executive Officer |
834.82K |
Sale |
2024-04-24 |
LARSON TINA MARRIOTT |
President |
543.23K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Baillie Gifford and Company |
25.10M |
187.48M |
12.30% |
2023-06-29 |
Blackrock Inc. |
11.62M |
86.80M |
5.69% |
2023-06-29 |
Vanguard Group Inc |
11.26M |
84.11M |
5.52% |
2023-09-29 |
Kinnevik Ab (publ) |
10.41M |
79.60M |
5.10% |
2023-06-29 |
MIC Capital Management UK LLP |
8.45M |
63.13M |
4.14% |
2023-09-29 |
ARK Investment Management, LLC |
6.88M |
52.61M |
3.37% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-09-29 |
ARK ETF Tr-ARK Genomic Revolution ETF |
6.80M |
52.00M |
3.33% |
2023-05-30 |
Vanguard U.S. Growth Fund |
3.97M |
34.85M |
1.95% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
3.52M |
26.29M |
1.72% |
2023-08-30 |
iShares Russell 2000 ETF |
3.12M |
27.14M |
1.53% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
2.86M |
21.37M |
1.40% |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
2.70M |
23.49M |
1.32% |